Cargando…

Corrigendum to “How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer”

Detalles Bibliográficos
Autores principales:	Prazeres, Hugo, Torres, Joana, Rodrigues, Fernando, Couto, Joana P., Vinagre, João, Sobrinho-Simões, Manuel, Soares, Paula
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2016
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940563/ https://www.ncbi.nlm.nih.gov/pubmed/27433368 http://dx.doi.org/10.1155/2016/2168046

Ejemplares similares

How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer
por: Prazeres, Hugo, et al.
Publicado: (2011)

AZD1480 Blocks Growth and Tumorigenesis of RET- Activated Thyroid Cancer Cell Lines
por: Couto, Joana P., et al.
Publicado: (2012)

Molecular Basis of Medullary Thyroid Carcinoma: The Role of RET Polymorphisms
por: Ceolin, Lucieli, et al.
Publicado: (2011)

Genetic Alterations in Poorly Differentiated and Undifferentiated Thyroid Carcinomas
por: Soares, Paula, et al.
Publicado: (2011)

Molecular Basis and Natural History of Medullary Thyroid Cancer: It is (Almost) All in the RET
por: Sahakian, Nicolas, et al.
Publicado: (2023)

Corrigendum to ‘How I treat medullary thyroid cancer’: [ESMO Open Volume 6, Issue 3, June 2021, 100183]
por: Kiesewetter, B., et al.
Publicado: (2022)

Allel RET+3 : T a medullary thyroid cancer
por: Pławski, A, et al.
Publicado: (2011)

Corrigendum: Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations
por: Oczko-Wojciechowska, Malgorzata, et al.
Publicado: (2017)

MON-562 Retrospective Analysis of Medullary Thyroid Carcinoma: Comparison between Individuals with and without RET Germline Mutation
por: Costa, Cláudia, et al.
Publicado: (2019)

Human thyroid tumours, the puzzling lessons from E7 and RET/PTC3 transgenic mice
por: Jin, L, et al.
Publicado: (2009)

Calcitonin receptor expression in medullary thyroid carcinoma
por: Cappagli, Virginia, et al.
Publicado: (2017)

Chinese siblings with hereditary medullary thyroid carcinoma caused by RET mutation: implications for RET oncogene detection
por: Huang, Qin, et al.
Publicado: (2020)

Corrigendum to: Interaction of transcription factor AP‐2 gamma with proto‐oncogene PELP1 promotes tumorigenesis by enhancing RET signaling
Publicado: (2021)

siRNA nanoformulation against the Ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma
por: de Martimprey, Henri, et al.
Publicado: (2008)

RET mutations in a large indian family with medullary thyroid carcinoma
por: Mahesh, D. M., et al.
Publicado: (2014)

RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases
por: Romei, Cristina, et al.
Publicado: (2018)

Modifier Role of Common RET Variants in Sporadic Medullary Thyroid Carcinoma
por: Skalniak, Anna, et al.
Publicado: (2021)

The Blood Biomarkers of Thyroid Cancer [Corrigendum]
Publicado: (2022)

Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas
por: Moura, M M, et al.
Publicado: (2009)

Somatic Mutations in the RET Protooncogene in Japanese and Chinese Sporadic Medullary Thyroid Carcinomas
por: Shan, Liang, et al.
Publicado: (1998)

Crude annual incidence rate of medullary thyroid cancer and RET mutation frequency
por: Milićević, Sara, et al.
Publicado: (2021)

Effect of 3′UTR RET Variants on RET mRNA Secondary Structure and Disease Presentation in Medullary Thyroid Carcinoma
por: Ceolin, Lucieli, et al.
Publicado: (2016)

Higher RET Gene Expression Levels Do Not Represent anAlternative RET Activation Mechanism in Medullary Thyroid Carcinoma
por: Mulè, Chiara, et al.
Publicado: (2021)

Corrigendum to “Does Size Matter? Mate Choice in Two Lekking Flies”
Publicado: (2020)

Molecular Aspects of Thyroid Calcification
por: Ferreira, Luciana Bueno, et al.
Publicado: (2020)

Corrigendum to: Structural basis for adPEO-causing mutations in the mitochondrial TWINKLE helicase
por: Peter, Bradley, et al.
Publicado: (2020)

Corrigendum to “Challenges in Interpretation of Thyroid Function Tests in Pregnant Women with Autoimmune Thyroid Disease”
por: Feldt-Rasmussen, Ulla, et al.
Publicado: (2017)

Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey
por: Aydoğan, Berna İmge, et al.
Publicado: (2016)

Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations
por: Oczko-Wojciechowska, Malgorzata, et al.
Publicado: (2017)

Novel Point Mutations and Allele Loss at the RET Locus in Sporadic Medullary Thyroid Carcinomas
por: Uchino, Shinya, et al.
Publicado: (1998)

Retroposed copies of RET gene: a somatically acquired event in medullary thyroid carcinoma
por: Bim, Larissa V., et al.
Publicado: (2019)

A BRAF V600E Mutation in RET-Negative Medullary Thyroid Cancer
por: Robbins, Richard J., et al.
Publicado: (2020)

Corrigendum to: The Role of Iodine for Thyroid Function in Lactating Women and Infants
Publicado: (2022)

RET Copy Number Alteration in Medullary Thyroid Cancer Is a Rare Event Correlated with RET Somatic Mutations and High Allelic Frequency
por: Ramone, Teresa, et al.
Publicado: (2020)

Corrigendum to “Redox Signaling in Diabetic Nephropathy: Hypertrophy versus Death Choices in Mesangial Cells and Podocytes”
por: Manda, Gina, et al.
Publicado: (2018)

Corrigendum to “Impact of Diabetic Ketoacidosis on Thyroid Function in Patients with Diabetes Mellitus”
por: Xing, Yuling, et al.
Publicado: (2021)

Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine
por: Kumarasamy, Vishnu Muthuraj, et al.
Publicado: (2015)

Large‐scale Analysis of Mutations in RET Exon 16 in Sporadic Medullary Thyroid Carcinomas in Japan
por: Takano, Torn, et al.
Publicado: (2001)

Selective Antitumor Activity of Datelliptium toward Medullary Thyroid Carcinoma by Downregulating RET Transcriptional Activity
por: Alqahtani, Tariq, et al.
Publicado: (2021)

TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma
por: Ye, Song, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sdh3hbklvulcid0rpef2n9n0li